Kyverna Therapeutics Inc
KYTX9.400USD
+0.410+4.56%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
411.66MMarket Cap
LossP/E TTM
More Details of Kyverna Therapeutics Inc Company
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The Company is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
Kyverna Therapeutics Inc Info
Ticker SymbolKYTX
Company nameKyverna Therapeutics Inc
IPO dateFeb 08, 2024
CEOBiddle (Warner Weston)
Number of employees112
Security typeOrdinary Share
Fiscal year-endFeb 08
Address5980 Horton Street
CityEMERYVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94608
Phone15106268331
Websitehttps://kyvernatx.com/
Ticker SymbolKYTX
IPO dateFeb 08, 2024
CEOBiddle (Warner Weston)
Company Executives of Kyverna Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director
Independent Director
16.63K
--
Mr. Mert Aktar
Mr. Mert Aktar
Independent Director
Independent Director
16.63K
--
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Independent Director
16.63K
--
Ms. Karen Walker
Ms. Karen Walker
Chief Technology Officer
Chief Technology Officer
9.64K
--
Ms. Christi Shaw
Ms. Christi Shaw
Independent Director
Independent Director
--
--
Mr. Daniel K. (Dan) Spiegelman
Mr. Daniel K. (Dan) Spiegelman
Independent Director
Independent Director
--
--
Mr. Ian T. Clark
Mr. Ian T. Clark
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Warner Biddle
Mr. Warner Biddle
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Dan Maziasz
Mr. Dan Maziasz
Chief Business Officer
Chief Business Officer
--
--
Ms. Tracy Rossin
Ms. Tracy Rossin
Senior Vice President - Corporate Affairs, Communications and Investor Relations
Senior Vice President - Corporate Affairs, Communications and Investor Relations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director
Independent Director
16.63K
--
Mr. Mert Aktar
Mr. Mert Aktar
Independent Director
Independent Director
16.63K
--
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Independent Director
16.63K
--
Ms. Karen Walker
Ms. Karen Walker
Chief Technology Officer
Chief Technology Officer
9.64K
--
Ms. Christi Shaw
Ms. Christi Shaw
Independent Director
Independent Director
--
--
Mr. Daniel K. (Dan) Spiegelman
Mr. Daniel K. (Dan) Spiegelman
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2023
FY2023Q4
FY2022
FY2022Q4
FY2021
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Nov 19
Updated: Wed, Nov 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Westlake Village BioPartners
7.92%
VV Manager LLC
7.92%
Gilead Sciences Inc
7.22%
Bain Capital Life Sciences Investors, LLC
5.90%
Northpond Ventures, LLC
5.70%
Other
65.34%
Shareholders
Shareholders
Proportion
Westlake Village BioPartners
7.92%
VV Manager LLC
7.92%
Gilead Sciences Inc
7.22%
Bain Capital Life Sciences Investors, LLC
5.90%
Northpond Ventures, LLC
5.70%
Other
65.34%
Shareholder Types
Shareholders
Proportion
Venture Capital
24.38%
Investment Advisor
22.83%
Corporation
7.22%
Investment Advisor/Hedge Fund
2.62%
Hedge Fund
2.38%
Individual Investor
1.88%
Research Firm
0.95%
Bank and Trust
0.01%
Other
37.72%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
249
27.63M
63.88%
-17.77M
2025Q2
249
34.71M
80.31%
-15.16M
2025Q1
241
34.71M
80.32%
-14.73M
2024Q4
219
37.31M
86.43%
-9.28M
2024Q3
197
37.54M
87.00%
-4.76M
2024Q2
169
41.21M
95.55%
+9.91M
2024Q1
122
39.94M
92.66%
+25.83M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Westlake Village BioPartners
4.52M
10.46%
--
--
Sep 30, 2024
VV Manager LLC
4.52M
10.46%
--
--
Jun 30, 2025
Gilead Sciences Inc
4.13M
9.54%
--
--
Jun 30, 2025
Bain Capital Life Sciences Investors, LLC
3.37M
7.79%
--
--
Jun 30, 2025
Northpond Ventures, LLC
3.26M
7.53%
--
--
Sep 30, 2024
T. Rowe Price Associates, Inc.
1.78M
4.11%
+1.25M
+235.49%
Jun 30, 2025
The Vanguard Group, Inc.
1.31M
3.04%
+14.32K
+1.10%
Jun 30, 2025
Insight Venture Partners
989.05K
2.29%
--
--
Jun 30, 2025
Medical Strategy GmbH
633.24K
1.46%
+633.24K
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares Micro-Cap ETF
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
iShares Biotechnology ETF
0.01%
Avantis US Small Cap Equity ETF
0.01%
iShares Morningstar Small-Cap ETF
0%
First Trust Multi-Manager Small Cap Opportunities ETF
0%
Schwab U.S. Small-Cap ETF
0%
iShares Health Innovation Active ETF
0%
Proshares Ultra Russell 2000
0%
View more
ProShares Ultra Nasdaq Biotechnology
Proportion0.04%
iShares Micro-Cap ETF
Proportion0.03%
Invesco Nasdaq Biotechnology ETF
Proportion0.03%
iShares Biotechnology ETF
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0.01%
iShares Morningstar Small-Cap ETF
Proportion0%
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion0%
Schwab U.S. Small-Cap ETF
Proportion0%
iShares Health Innovation Active ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Kyverna Therapeutics Inc?
The top five shareholders of Kyverna Therapeutics Inc are:
Westlake Village BioPartners holds 4.52M shares, accounting for 10.46% of the total shares.
VV Manager LLC holds 4.52M shares, accounting for 10.46% of the total shares.
Gilead Sciences Inc holds 4.13M shares, accounting for 9.54% of the total shares.
Bain Capital Life Sciences Investors, LLC holds 3.37M shares, accounting for 7.79% of the total shares.
Northpond Ventures, LLC holds 3.26M shares, accounting for 7.53% of the total shares.
Westlake Village BioPartners holds 4.52M shares, accounting for 10.46% of the total shares.
VV Manager LLC holds 4.52M shares, accounting for 10.46% of the total shares.
Gilead Sciences Inc holds 4.13M shares, accounting for 9.54% of the total shares.
Bain Capital Life Sciences Investors, LLC holds 3.37M shares, accounting for 7.79% of the total shares.
Northpond Ventures, LLC holds 3.26M shares, accounting for 7.53% of the total shares.
What are the top three shareholder types of Kyverna Therapeutics Inc?
The top three shareholder types of Kyverna Therapeutics Inc are:
Westlake Village BioPartners
VV Manager LLC
Gilead Sciences Inc
Westlake Village BioPartners
VV Manager LLC
Gilead Sciences Inc
How many institutions hold shares of Kyverna Therapeutics Inc (KYTX)?
As of 2025Q3, 249 institutions hold shares of Kyverna Therapeutics Inc, with a combined market value of approximately 27.63M, accounting for 63.88% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -16.43%.
What is the biggest source of revenue for Kyverna Therapeutics Inc?
In FY2023, the -- business generated the highest revenue for Kyverna Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
